Search

Your search keyword '"D'Angelo, Sandra P"' showing total 503 results
Start Over Author "D'Angelo, Sandra P"
503 results on '"D'Angelo, Sandra P"'

1. Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy

Author

Subramanian, Ajay, Nemat-Gorgani, Neda, Ellis-Caleo, Timothy J., van IJzendoorn, David G. P., Sears, Timothy J., Somani, Anish, Luca, Bogdan A., Zhou, Maggie Y., Bradic, Martina, Torres, Ileana A., Oladipo, Eniola, New, Christin, Kenney, Deborah E., Avedian, Raffi S., Steffner, Robert J., Binkley, Michael S., Mohler, David G., Tap, William D., D’Angelo, Sandra P., van de Rijn, Matt, Ganjoo, Kristen N., Bui, Nam Q., Charville, Gregory W., Newman, Aaron M., and Moding, Everett J.

Published
2024
Full Text
View/download PDF

2. Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma

Author

Gyurdieva, Alexandra, Zajic, Stefan, Chang, Ya-Fang, Houseman, E Andres, Zhong, Shan, Kim, Jaegil, Nathenson, Michael, Faitg, Thomas, Woessner, Mary, Turner, David C, Hasan, Aisha N, Glod, John, Kaplan, Rosandra N, D’Angelo, Sandra P, Araujo, Dejka M, Chow, Warren A, Druta, Mihaela, Demetri, George D, Van Tine, Brian A, Grupp, Stephan A, Fine, Gregg D, and Eleftheriadou, Ioanna

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Clinical Research, Development of treatments and therapeutic interventions, 5.2 Cellular and gene therapies, Antigens, Neoplasm, Biomarkers, CD8-Positive T-Lymphocytes, Humans, Membrane Proteins, Receptors, Antigen, T-Cell, Sarcoma, Synovial, Tumor Microenvironment
Abstract

Autologous T cells transduced to express a high affinity T-cell receptor specific to NY-ESO-1 (letetresgene autoleucel, lete-cel) show promise in the treatment of metastatic synovial sarcoma, with 50% overall response rate. The efficacy of lete-cel treatment in 45 synovial sarcoma patients (NCT01343043) has been previously reported, however, biomarkers predictive of response and resistance remain to be better defined. This post-hoc analysis identifies associations of response to lete-cel with lymphodepleting chemotherapy regimen (LDR), product attributes, cell expansion, cytokines, and tumor gene expression. Responders have higher IL-15 levels pre-infusion (p = 0.011) and receive a higher number of transduced effector memory (CD45RA- CCR7-) CD8 + cells per kg (p = 0.039). Post-infusion, responders have increased IFNγ, IL-6, and peak cell expansion (p

Published
2022

4. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial

Author

D'Angelo, Sandra P, Araujo, Dejka M, Abdul Razak, Albiruni R, Agulnik, Mark, Attia, Steven, Blay, Jean-Yves, Carrasco Garcia, Irene, Charlson, John A, Choy, Edwin, Demetri, George D, Druta, Mihaela, Forcade, Edouard, Ganjoo, Kristen N, Glod, John, Keedy, Vicki L, Le Cesne, Axel, Liebner, David A, Moreno, Victor, Pollack, Seth M, Schuetze, Scott M, Schwartz, Gary K, Strauss, Sandra J, Tap, William D, Thistlethwaite, Fiona, Valverde Morales, Claudia Maria, Wagner, Michael J, Wilky, Breelyn A, McAlpine, Cheryl, Hudson, Laura, Navenot, Jean-Marc, Wang, Tianjiao, Bai, Jane, Rafail, Stavros, Wang, Ruoxi, Sun, Amy, Fernandes, Lilliam, Van Winkle, Erin, Elefant, Erica, Lunt, Colin, Norry, Elliot, Williams, Dennis, Biswas, Swethajit, and Van Tine, Brian A

Published
2024
Full Text
View/download PDF

5. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

Author

Gounder, Mrinal M, Agaram, Narasimhan P, Trabucco, Sally E, Robinson, Victoria, Ferraro, Richard A, Millis, Sherri Z, Krishnan, Anita, Lee, Jessica, Attia, Steven, Abida, Wassim, Drilon, Alexander, Chi, Ping, Angelo, Sandra P D’, Dickson, Mark A, Keohan, Mary Lou, Kelly, Ciara M, Agulnik, Mark, Chawla, Sant P, Choy, Edwin, Chugh, Rashmi, Meyer, Christian F, Myer, Parvathi A, Moore, Jessica L, Okimoto, Ross A, Pollock, Raphael E, Ravi, Vinod, Singh, Arun S, Somaiah, Neeta, Wagner, Andrew J, Healey, John H, Frampton, Garrett M, Venstrom, Jeffrey M, Ross, Jeffrey S, Ladanyi, Marc, Singer, Samuel, Brennan, Murray F, Schwartz, Gary K, Lazar, Alexander J, Thomas, David M, Maki, Robert G, Tap, William D, Ali, Siraj M, and Jin, Dexter X

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Genetics, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Biotechnology, Clinical Research, Human Genome, Genetic Testing, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Biomarkers, Tumor, Bone Neoplasms, Genomics, Humans, Mutation, Osteosarcoma, Prospective Studies, Sarcoma
Abstract

There are more than 70 distinct sarcomas, and this diversity complicates the development of precision-based therapeutics for these cancers. Prospective comprehensive genomic profiling could overcome this challenge by providing insight into sarcomas' molecular drivers. Through targeted panel sequencing of 7494 sarcomas representing 44 histologies, we identify highly recurrent and type-specific alterations that aid in diagnosis and treatment decisions. Sequencing could lead to refinement or reassignment of 10.5% of diagnoses. Nearly one-third of patients (31.7%) harbor potentially actionable alterations, including a significant proportion (2.6%) with kinase gene rearrangements; 3.9% have a tumor mutational burden ≥10 mut/Mb. We describe low frequencies of microsatellite instability (

Published
2022

6. Stereotactic body radiation therapy for sarcoma pulmonary metastases

Author

Lebow, Emily S., Lobaugh, Stephanie M., Zhang, Zhigang, Dickson, Mark A., Rosenbaum, Evan, D'Angelo, Sandra P., Nacev, Benjamin A., Shepherd, Annemarie F., Shaverdian, Narek, Wolden, Suzanne, Wu, Abraham J., Gelblum, Daphna Y., Simone, Charles B., II, Gomez, Daniel R., Alektiar, Kaled, Tap, William D., and Rimner, Andreas

Published
2023
Full Text
View/download PDF

7. Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response

Author

Kasago, Israel S., Chatila, Walid K., Lezcano, Cecilia M., Febres-Aldana, Christopher A., Schultz, Nikolaus, Vanderbilt, Chad, Dogan, Snjezana, Bartlett, Edmund K., D’Angelo, Sandra P., Tap, William D., Singer, Samuel, Ladanyi, Marc, Shoushtari, Alexander N., Busam, Klaus J., and Hameed, Meera

Published
2023
Full Text
View/download PDF

8. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma

Author

Ramachandran, Indu, Lowther, Daniel E, Dryer-Minnerly, Rebecca, Wang, Ruoxi, Fayngerts, Svetlana, Nunez, Daniel, Betts, Gareth, Bath, Natalie, Tipping, Alex J, Melchiori, Luca, Navenot, Jean-Marc, Glod, John, Mackall, Crystal L, D’Angelo, Sandra P, Araujo, Dejka M, Chow, Warren A, Demetri, George D, Druta, Mihaela, Van Tine, Brian A, Grupp, Stephan A, Abdul Razak, Albiruni R, Wilky, Breelyn, Iyengar, Malini, Trivedi, Trupti, Winkle, Erin Van, Chagin, Karen, Amado, Rafael, Binder, Gwendolyn K, and Basu, Samik

Subjects
Vaccine Related, Biotechnology, Immunization, Cancer, Clinical Research, 2.1 Biological and endogenous factors, Aetiology, Antigens, Neoplasm, Biomarkers, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Cytokines, Cytotoxicity, Immunologic, HLA-A Antigens, Humans, Immunohistochemistry, Immunotherapy, Adoptive, Lymphocytes, Tumor-Infiltrating, Membrane Proteins, Receptors, Antigen, T-Cell, Receptors, Chimeric Antigen, Sarcoma, Synovial, T-Cell Antigen Receptor Specificity, T-Lymphocytes, Treatment Outcome, Tumor Microenvironment, Adoptive immunotherapy, Synovial sarcoma, NY-ESO-1, Fludarabine, Cyclophosphamide, T cell, TCR, IL-15, Cytokine, Antigen loss, Checkpoint therapy, Engineered cell therapy
Abstract

BackgroundGene-modified autologous T cells expressing NY-ESO-1c259, an affinity-enhanced T-cell receptor (TCR) reactive against the NY-ESO-1-specific HLA-A*02-restricted peptide SLLMWITQC (NY-ESO-1 SPEAR T-cells; GSK 794), have demonstrated clinical activity in patients with advanced synovial sarcoma (SS). The factors contributing to gene-modified T-cell expansion and the changes within the tumor microenvironment (TME) following T-cell infusion remain unclear. These studies address the immunological mechanisms of response and resistance in patients with SS treated with NY-ESO-1 SPEAR T-cells.MethodsFour cohorts were included to evaluate antigen expression and preconditioning on efficacy. Clinical responses were assessed by RECIST v1.1. Engineered T-cell persistence was determined by qPCR. Serum cytokines were evaluated by immunoassay. Transcriptomic analyses and immunohistochemistry were performed on tumor biopsies from patients before and after T-cell infusion. Gene-modified T-cells were detected within the TME via an RNAish assay.ResultsResponses across cohorts were affected by preconditioning and intra-tumoral NY-ESO-1 expression. Of the 42 patients reported (data cut-off 4June2018), 1 patient had a complete response, 14 patients had partial responses, 24 patients had stable disease, and 3 patients had progressive disease. The magnitude of gene-modified T-cell expansion shortly after infusion was associated with response in patients with high intra-tumoral NY-ESO-1 expression. Patients receiving a fludarabine-containing conditioning regimen experienced increases in serum IL-7 and IL-15. Prior to infusion, the TME exhibited minimal leukocyte infiltration; CD163+ tumor-associated macrophages (TAMs) were the dominant population. Modest increases in intra-tumoral leukocytes (≤5%) were observed in a subset of subjects at approximately 8 weeks. Beyond 8 weeks post infusion, the TME was minimally infiltrated with a TAM-dominant leukocyte infiltrate. Tumor-associated antigens and antigen presentation did not significantly change within the tumor post-T-cell infusion. Finally, NY-ESO-1 SPEAR T cells trafficked to the TME and maintained cytotoxicity in a subset of patients.ConclusionsOur studies elucidate some factors that underpin response and resistance to NY-ESO-1 SPEAR T-cell therapy. From these data, we conclude that a lymphodepletion regimen containing high doses of fludarabine and cyclophosphamide is necessary for SPEAR T-cell persistence and efficacy. Furthermore, these data demonstrate that non-T-cell inflamed tumors, which are resistant to PD-1/PD-L1 inhibitors, can be treated with adoptive T-cell based immunotherapy.Trial registrationClinicalTrials.gov, NCT01343043 , Registered 27 April 2011.

Published
2019

10. A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery

Author

Rosenbaum, Evan, Chugh, Rashmi, Ryan, Christopher W., Agulnik, Mark, Milhem, Mohammed M., George, Suzanne, Jones, Robin L., Chmielowski, Bartosz, Van Tine, Brian A., Tawbi, Hussein, Elias, Anthony D., Read, William L., Budd, G. Thomas, Qin, Li-Xuan, Rodler, Eve T., Hirman, Joe, Weiden, Paul, Bennett, Cathryn M., Livingston, Philip O., Ragupathi, Govind, Hansen, David, D'Angelo, Sandra P., Tap, William D., Schwartz, Gary K., Maki, Robert G., and Carvajal, Richard D.

Published
2022
Full Text
View/download PDF

13. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

Author

Nacev, Benjamin A., Sanchez-Vega, Francisco, Smith, Shaleigh A., Antonescu, Cristina R., Rosenbaum, Evan, Shi, Hongyu, Tang, Cerise, Socci, Nicholas D., Rana, Satshil, Gularte-Mérida, Rodrigo, Zehir, Ahmet, Gounder, Mrinal M., Bowler, Timothy G., Luthra, Anisha, Jadeja, Bhumika, Okada, Azusa, Strong, Jonathan A., Stoller, Jake, Chan, Jason E., Chi, Ping, D’Angelo, Sandra P., Dickson, Mark A., Kelly, Ciara M., Keohan, Mary Louise, Movva, Sujana, Thornton, Katherine, Meyers, Paul A., Wexler, Leonard H., Slotkin, Emily K., Glade Bender, Julia L., Shukla, Neerav N., Hensley, Martee L., Healey, John H., La Quaglia, Michael P., Alektiar, Kaled M., Crago, Aimee M., Yoon, Sam S., Untch, Brian R., Chiang, Sarah, Agaram, Narasimhan P., Hameed, Meera R., Berger, Michael F., Solit, David B., Schultz, Nikolaus, Ladanyi, Marc, Singer, Samuel, and Tap, William D.

Published
2022
Full Text
View/download PDF

14. Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma

Author

D’Angelo, Sandra P., Richards, Allison L., Conley, Anthony P., Woo, Hyung Jun, Dickson, Mark A., Gounder, Mrinal, Kelly, Ciara, Keohan, Mary Louise, Movva, Sujana, Thornton, Katherine, Rosenbaum, Evan, Chi, Ping, Nacev, Benjamin, Chan, Jason E., Slotkin, Emily K., Kiesler, Hannah, Adamson, Travis, Ling, Lilan, Rao, Pavitra, Patel, Shreyaskumar, Livingston, Jonathan A., Singer, Samuel, Agaram, Narasimhan P., Antonescu, Cristina R., Koff, Andrew, Erinjeri, Joseph P., Hwang, Sinchun, Qin, Li-Xuan, Donoghue, Mark T. A., and Tap, William D.

Published
2022
Full Text
View/download PDF

16. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

Author

Larkin, James, Minor, David, D'Angelo, Sandra, Neyns, Bart, Smylie, Michael, Miller, Wilson H, Gutzmer, Ralf, Linette, Gerald, Chmielowski, Bartosz, Lao, Christopher D, Lorigan, Paul, Grossmann, Kenneth, Hassel, Jessica C, Sznol, Mario, Daud, Adil, Sosman, Jeffrey, Khushalani, Nikhil, Schadendorf, Dirk, Hoeller, Christoph, Walker, Dana, Kong, George, Horak, Christine, and Weber, Jeffrey

Subjects
Clinical Trials and Supportive Activities, Cancer, Patient Safety, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Administration, Intravenous, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Dacarbazine, Disease Progression, Drug Administration Schedule, Female, Humans, Male, Melanoma, Middle Aged, Nivolumab, Paclitaxel, Progression-Free Survival, Skin Neoplasms, Time Factors, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose Until recently, limited options existed for patients with advanced melanoma who experienced disease progression while receiving treatment with ipilimumab. Here, we report the coprimary overall survival (OS) end point of CheckMate 037, which has previously shown that nivolumab resulted in more patients achieving an objective response compared with chemotherapy regimens in ipilimumab-refractory patients with advanced melanoma. Patients and Methods Patients were stratified by programmed death-ligand 1 expression, BRAF status, and best prior cytotoxic T-lymphocyte antigen-4 therapy response, then randomly assigned 2:1 to nivolumab 3 mg/kg intravenously every 2 weeks or investigator's choice chemotherapy (ICC; dacarbazine 1,000 mg/m2 every 3 weeks or carboplatin area under the curve 6 plus paclitaxel 175 mg/m2 every 3 weeks). Patients were treated until they experienced progression or unacceptable toxicity, with follow-up of approximately 2 years. Results Two hundred seventy-two patients were randomly assigned to nivolumab (99% treated) and 133 to ICC (77% treated). More nivolumab-treated patients had brain metastases (20% v 14%) and increased lactate dehydrogenase levels (52% v 38%) at baseline; 41% of patients treated with ICC versus 11% of patients treated with nivolumab received anti-programmed death 1 agents after randomly assigned therapy. Median OS was 16 months for nivolumab versus 14 months for ICC (hazard ratio, 0.95; 95.54% CI, 0.73 to 1.24); median progression-free survival was 3.1 months versus 3.7 months, respectively (hazard ratio, 1.0; 95.1% CI, 0.78 to 1.436). Overall response rate (27% v 10%) and median duration of response (32 months v 13 months) were notably higher for nivolumab versus ICC. Fewer grade 3 and 4 treatment-related adverse events were observed in patients on nivolumab (14% v 34%). Conclusion Nivolumab demonstrated higher, more durable responses but no difference in survival compared with ICC. OS should be interpreted with caution as it was likely impacted by an increased dropout rate before treatment, which led to crossover therapy in the ICC group, and by an increased proportion of patients in the nivolumab group with poor prognostic factors.

Published
2018

18. Supplementary Table S3 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

Author

Gleason, Caroline E., primary, Dickson, Mark A., primary, Klein (Dooley), Mary E., primary, Antonescu, Cristina R., primary, Gularte-Mérida, Rodrigo, primary, Benitez, Marimar, primary, Delgado, Juliana I., primary, Kataru, Raghu P., primary, Tan, Mark Wei Yi, primary, Bradic, Martina, primary, Adamson, Travis E., primary, Seier, Kenneth, primary, Richards, Allison L., primary, Palafox, Marta, primary, Chan, Eric, primary, D'Angelo, Sandra P., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Kelly, Ciara M., primary, Chi, Ping, primary, Movva, Sujana, primary, Landa, Jonathan, primary, Crago, Aimee M., primary, Donoghue, Mark T.A., primary, Qin, Li-Xuan, primary, Serra, Violetta, primary, Turkekul, Mesruh, primary, Barlas, Afsar, primary, Firester, Daniel M., primary, Manova-Todorova, Katia, primary, Mehrara, Babak J., primary, Kovatcheva, Marta, primary, Tan, Nguan Soon, primary, Singer, Samuel, primary, Tap, William D., primary, and Koff, Andrew, primary

Published
2024
Full Text
View/download PDF

19. Supplementary Figure S15 from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

Author

Gleason, Caroline E., primary, Dickson, Mark A., primary, Klein (Dooley), Mary E., primary, Antonescu, Cristina R., primary, Gularte-Mérida, Rodrigo, primary, Benitez, Marimar, primary, Delgado, Juliana I., primary, Kataru, Raghu P., primary, Tan, Mark Wei Yi, primary, Bradic, Martina, primary, Adamson, Travis E., primary, Seier, Kenneth, primary, Richards, Allison L., primary, Palafox, Marta, primary, Chan, Eric, primary, D'Angelo, Sandra P., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Kelly, Ciara M., primary, Chi, Ping, primary, Movva, Sujana, primary, Landa, Jonathan, primary, Crago, Aimee M., primary, Donoghue, Mark T.A., primary, Qin, Li-Xuan, primary, Serra, Violetta, primary, Turkekul, Mesruh, primary, Barlas, Afsar, primary, Firester, Daniel M., primary, Manova-Todorova, Katia, primary, Mehrara, Babak J., primary, Kovatcheva, Marta, primary, Tan, Nguan Soon, primary, Singer, Samuel, primary, Tap, William D., primary, and Koff, Andrew, primary

Published
2024
Full Text
View/download PDF

20. Data from Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

Author

Gleason, Caroline E., primary, Dickson, Mark A., primary, Klein (Dooley), Mary E., primary, Antonescu, Cristina R., primary, Gularte-Mérida, Rodrigo, primary, Benitez, Marimar, primary, Delgado, Juliana I., primary, Kataru, Raghu P., primary, Tan, Mark Wei Yi, primary, Bradic, Martina, primary, Adamson, Travis E., primary, Seier, Kenneth, primary, Richards, Allison L., primary, Palafox, Marta, primary, Chan, Eric, primary, D'Angelo, Sandra P., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Kelly, Ciara M., primary, Chi, Ping, primary, Movva, Sujana, primary, Landa, Jonathan, primary, Crago, Aimee M., primary, Donoghue, Mark T.A., primary, Qin, Li-Xuan, primary, Serra, Violetta, primary, Turkekul, Mesruh, primary, Barlas, Afsar, primary, Firester, Daniel M., primary, Manova-Todorova, Katia, primary, Mehrara, Babak J., primary, Kovatcheva, Marta, primary, Tan, Nguan Soon, primary, Singer, Samuel, primary, Tap, William D., primary, and Koff, Andrew, primary

Published
2024
Full Text
View/download PDF

21. Immune checkpoint inhibitor response in sarcomas associates with immune infiltrates and increased expression of transposable elements and viral response pathways

Author

Nacev, Benjamin A., primary, Bradic, Martina, additional, Woo, Hyung Jun, additional, Richards, Allison L., additional, Kelly, Ciara M., additional, Dickson, Mark A., additional, Gounder, Mrinal M., additional, Keohan, Mary L., additional, Chi, Ping, additional, Movva, Sujana, additional, Maki, Robert, additional, Slotkin, Emily K., additional, Rosenbaum, Evan, additional, Avutu, Viswatej, additional, Chan, Jason E., additional, Banks, Lauren, additional, Adamson, Travis, additional, Singer, Samuel, additional, Antonescu, Cristina R., additional, Tap, William D., additional, Donoghue, Mark T.A., additional, and D’Angelo, Sandra P., additional

Published
2024
Full Text
View/download PDF

23. Supplementary Data from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, primary, Bradic, Martina, primary, Kelly, Ciara, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Avutu, Viswatej, primary, Chi, Ping, primary, Thornton, Katherine A., primary, Chan, Jason E., primary, Dickson, Mark A., primary, Donoghue, Mark T.A., primary, Tap, William D., primary, Qin, Li-Xuan, primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

24. TABLE 3 from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, primary, Bradic, Martina, primary, Kelly, Ciara, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Avutu, Viswatej, primary, Chi, Ping, primary, Thornton, Katherine A., primary, Chan, Jason E., primary, Dickson, Mark A., primary, Donoghue, Mark T.A., primary, Tap, William D., primary, Qin, Li-Xuan, primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

25. TABLE 4 from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, primary, Bradic, Martina, primary, Kelly, Ciara, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Avutu, Viswatej, primary, Chi, Ping, primary, Thornton, Katherine A., primary, Chan, Jason E., primary, Dickson, Mark A., primary, Donoghue, Mark T.A., primary, Tap, William D., primary, Qin, Li-Xuan, primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

26. Data from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, primary, Bradic, Martina, primary, Kelly, Ciara, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Avutu, Viswatej, primary, Chi, Ping, primary, Thornton, Katherine A., primary, Chan, Jason E., primary, Dickson, Mark A., primary, Donoghue, Mark T.A., primary, Tap, William D., primary, Qin, Li-Xuan, primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

27. TABLE 2 from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, primary, Bradic, Martina, primary, Kelly, Ciara, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Avutu, Viswatej, primary, Chi, Ping, primary, Thornton, Katherine A., primary, Chan, Jason E., primary, Dickson, Mark A., primary, Donoghue, Mark T.A., primary, Tap, William D., primary, Qin, Li-Xuan, primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

28. TABLE 1 from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, primary, Bradic, Martina, primary, Kelly, Ciara, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Avutu, Viswatej, primary, Chi, Ping, primary, Thornton, Katherine A., primary, Chan, Jason E., primary, Dickson, Mark A., primary, Donoghue, Mark T.A., primary, Tap, William D., primary, Qin, Li-Xuan, primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

29. Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas

Author

Rosenbaum, Evan, primary, Seier, Kenneth, additional, Bradic, Martina, additional, Kelly, Ciara, additional, Movva, Sujana, additional, Nacev, Benjamin A., additional, Gounder, Mrinal M., additional, Keohan, Mary L., additional, Avutu, Viswatej, additional, Chi, Ping, additional, Thornton, Katherine A., additional, Chan, Jason E., additional, Dickson, Mark A., additional, Donoghue, Mark T.A., additional, Tap, William D., additional, Qin, Li-Xuan, additional, and D'Angelo, Sandra P., additional

Published
2023
Full Text
View/download PDF

30. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors

Author

Kim, Tae Won, primary, Bedard, Philippe L., additional, LoRusso, Patricia, additional, Gordon, Michael S., additional, Bendell, Johanna, additional, Oh, Do-Youn, additional, Ahn, Myung-Ju, additional, Garralda, Elena, additional, D’Angelo, Sandra P., additional, Desai, Jayesh, additional, Hodi, F. Stephen, additional, Wainberg, Zev, additional, Delord, Jean-Pierre, additional, Cassier, Phillippe A., additional, Cervantes, Andrés, additional, Gil-Martin, Marta, additional, Wu, Benjamin, additional, Patil, Namrata S., additional, Jin, Yanling, additional, Hoang, Tien, additional, Mendus, Diana, additional, Wen, Xiaohui, additional, Meng, Raymond, additional, and Cho, Byoung Chul, additional

Published
2023
Full Text
View/download PDF

31. Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma

Author

Gleason, Caroline E., primary, Dickson, Mark A., additional, Klein (Dooley), Mary E., additional, Antonescu, Cristina R., additional, Gularte-Mérida, Rodrigo, additional, Benitez, Marimar, additional, Delgado, Juliana I., additional, Kataru, Raghu P., additional, Tan, Mark Wei Yi, additional, Bradic, Martina, additional, Adamson, Travis E., additional, Seier, Kenneth, additional, Richards, Allison L., additional, Palafox, Marta, additional, Chan, Eric, additional, D'Angelo, Sandra P., additional, Gounder, Mrinal M., additional, Keohan, Mary Louise, additional, Kelly, Ciara M., additional, Chi, Ping, additional, Movva, Sujana, additional, Landa, Jonathan, additional, Crago, Aimee M., additional, Donoghue, Mark T.A., additional, Qin, Li-Xuan, additional, Serra, Violetta, additional, Turkekul, Mesruh, additional, Barlas, Afsar, additional, Firester, Daniel M., additional, Manova-Todorova, Katia, additional, Mehrara, Babak J., additional, Kovatcheva, Marta, additional, Tan, Nguan Soon, additional, Singer, Samuel, additional, Tap, William D., additional, and Koff, Andrew, additional

Published
2023
Full Text
View/download PDF

32. Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma

Author

D’Angelo, Sandra P., Hunger, Matthias, Brohl, Andrew S., Nghiem, Paul, Bhatia, Shailender, Hamid, Omid, Mehnert, Janice M., Terheyden, Patrick, Shih, Kent C., Brownell, Isaac, Lebbé, Céleste, Lewis, Karl D., Linette, Gerald P., Milella, Michele, Schlichting, Michael, Hennessy, Meliessa H., and Bharmal, Murtuza

Published
2019
Full Text
View/download PDF

33. A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor

Author

Kelly, Ciara M., Shoushtari, Alexander N., Qin, Li-Xuan, D’Angelo, Sandra P., Dickson, Mark A., Gounder, Mrinal M., Keohan, Mary Louise, Mcfadyen, Chloe, Sjoberg, Ana, Singer, Samuel, DeMatteo, Ronald P., Hwang, Sinchun, Heinemann, M. H., Francis, Jasmine H., Antonescu, Cristina R., Chi, Ping, and Tap, William D.

Published
2019
Full Text
View/download PDF

34. Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Author

Samstein, Robert M., Lee, Chung-Han, Shoushtari, Alexander N., Hellmann, Matthew D., Shen, Ronglai, Janjigian, Yelena Y., Barron, David A., Zehir, Ahmet, Jordan, Emmet J., Omuro, Antonio, Kaley, Thomas J., Kendall, Sviatoslav M., Motzer, Robert J., Hakimi, A. Ari, Voss, Martin H., Russo, Paul, Rosenberg, Jonathan, Iyer, Gopa, Bochner, Bernard H., Bajorin, Dean F., Al-Ahmadie, Hikmat A., Chaft, Jamie E., Rudin, Charles M., Riely, Gregory J., Baxi, Shrujal, Ho, Alan L., Wong, Richard J., Pfister, David G., Wolchok, Jedd D., Barker, Christopher A., Gutin, Philip H., Brennan, Cameron W., Tabar, Viviane, Mellinghoff, Ingo K., DeAngelis, Lisa M., Ariyan, Charlotte E., Lee, Nancy, Tap, William D., Gounder, Mrinal M., D’Angelo, Sandra P., Saltz, Leonard, Stadler, Zsofia K., Scher, Howard I., Baselga, Jose, Razavi, Pedram, Klebanoff, Christopher A., Yaeger, Rona, Segal, Neil H., Ku, Geoffrey Y., DeMatteo, Ronald P., Ladanyi, Marc, Rizvi, Naiyer A., Berger, Michael F., Riaz, Nadeem, Solit, David B., Chan, Timothy A., and Morris, Luc G. T.

Published
2019
Full Text
View/download PDF

35. Supplementary Data 2 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma

Author

Kelly, Ciara M., primary, Qin, Li-Xuan, primary, Whiting, Karissa A., primary, Richards, Allison L., primary, Avutu, Viswatej, primary, Chan, Jason E., primary, Chi, Ping, primary, Dickson, Mark A., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Rosenbaum, Evan, primary, Adamson, Travis, primary, Singer, Samuel, primary, Bartlett, Edmund K., primary, Crago, Aimee M., primary, Yoon, Sam S., primary, Hwang, Sinchun, primary, Erinjeri, Joseph P., primary, Antonescu, Cristina R., primary, Tap, William D., primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

36. A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with advanced sarcoma: Results of expansion cohorts.

Author

Kelly, Ciara Marie, primary, Avutu, Viswatej, additional, Chi, Ping, additional, Dickson, Mark Andrew, additional, Gounder, Mrinal M., additional, Keohan, Mary Louise, additional, Movva, Sujana, additional, Rosenbaum, Evan, additional, Cordover, Emma, additional, Ariyan, Charlotte Eielson, additional, Bartlett, Edmund, additional, Crago, Aimee Marie, additional, Singer, Samuel, additional, Antonescu, Cristina R., additional, Hwang, Sinchun, additional, Erinjeri, Joseph Patrick, additional, Seier, Kenneth, additional, Qin, Li-Xuan, additional, Tap, William D., additional, and D'Angelo, Sandra P., additional

Published
2023
Full Text
View/download PDF

37. Supplementary Data 1 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma

Author

Kelly, Ciara M., primary, Qin, Li-Xuan, primary, Whiting, Karissa A., primary, Richards, Allison L., primary, Avutu, Viswatej, primary, Chan, Jason E., primary, Chi, Ping, primary, Dickson, Mark A., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Rosenbaum, Evan, primary, Adamson, Travis, primary, Singer, Samuel, primary, Bartlett, Edmund K., primary, Crago, Aimee M., primary, Yoon, Sam S., primary, Hwang, Sinchun, primary, Erinjeri, Joseph P., primary, Antonescu, Cristina R., primary, Tap, William D., primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Data 3 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma

Author

Kelly, Ciara M., primary, Qin, Li-Xuan, primary, Whiting, Karissa A., primary, Richards, Allison L., primary, Avutu, Viswatej, primary, Chan, Jason E., primary, Chi, Ping, primary, Dickson, Mark A., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Rosenbaum, Evan, primary, Adamson, Travis, primary, Singer, Samuel, primary, Bartlett, Edmund K., primary, Crago, Aimee M., primary, Yoon, Sam S., primary, Hwang, Sinchun, primary, Erinjeri, Joseph P., primary, Antonescu, Cristina R., primary, Tap, William D., primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

41. Data from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma

Author

Kelly, Ciara M., primary, Qin, Li-Xuan, primary, Whiting, Karissa A., primary, Richards, Allison L., primary, Avutu, Viswatej, primary, Chan, Jason E., primary, Chi, Ping, primary, Dickson, Mark A., primary, Gounder, Mrinal M., primary, Keohan, Mary Louise, primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Rosenbaum, Evan, primary, Adamson, Travis, primary, Singer, Samuel, primary, Bartlett, Edmund K., primary, Crago, Aimee M., primary, Yoon, Sam S., primary, Hwang, Sinchun, primary, Erinjeri, Joseph P., primary, Antonescu, Cristina R., primary, Tap, William D., primary, and D'Angelo, Sandra P., primary

Published
2023
Full Text
View/download PDF

42. Abstract 5960: Identification and validation of sarcoma cellular ecosystems associated with prognosis and predictive of immunotherapy response

Author

Subramanian, Ajay, primary, Nemat-Gorgani, Neda, additional, Ellis-Caleo, Timothy J., additional, van IJzendoorn, David G.P., additional, Sears, Timothy J., additional, Somani, Anish, additional, Luca, Bogdan A., additional, Zhou, Maggie Y., additional, Bradic, Martina, additional, Torres, Ileana A., additional, Oladipo, Eniola, additional, New, Christin, additional, Kenney, Deborah E., additional, Avedian, Raffi S., additional, Steffner, Robert J., additional, Binkley, Michael S., additional, Mohler, David G., additional, Tap, William D., additional, D’Angelo, Sandra P., additional, van de Rijn, Matt, additional, Ganjoo, Kristen N., additional, Bui, Nam Q., additional, Charville, Gregory W., additional, Newman, Aaron M., additional, and Moding, Everett J., additional

Published
2023
Full Text
View/download PDF

43. Data from Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma

Author

D'Angelo, Sandra P., primary, Melchiori, Luca, primary, Merchant, Melinda S., primary, Bernstein, Donna, primary, Glod, John, primary, Kaplan, Rosandra, primary, Grupp, Stephan, primary, Tap, William D., primary, Chagin, Karen, primary, Binder, Gwendolyn K., primary, Basu, Samik, primary, Lowther, Daniel E., primary, Wang, Ruoxi, primary, Bath, Natalie, primary, Tipping, Alex, primary, Betts, Gareth, primary, Ramachandran, Indu, primary, Navenot, Jean-Marc, primary, Zhang, Hua, primary, Wells, Daniel K., primary, Van Winkle, Erin, primary, Kari, Gabor, primary, Trivedi, Trupti, primary, Holdich, Tom, primary, Pandite, Lini, primary, Amado, Rafael, primary, and Mackall, Crystal L., primary

Published
2023
Full Text
View/download PDF

44. Figures S1-S7 from Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma

Author

D'Angelo, Sandra P., primary, Melchiori, Luca, primary, Merchant, Melinda S., primary, Bernstein, Donna, primary, Glod, John, primary, Kaplan, Rosandra, primary, Grupp, Stephan, primary, Tap, William D., primary, Chagin, Karen, primary, Binder, Gwendolyn K., primary, Basu, Samik, primary, Lowther, Daniel E., primary, Wang, Ruoxi, primary, Bath, Natalie, primary, Tipping, Alex, primary, Betts, Gareth, primary, Ramachandran, Indu, primary, Navenot, Jean-Marc, primary, Zhang, Hua, primary, Wells, Daniel K., primary, Van Winkle, Erin, primary, Kari, Gabor, primary, Trivedi, Trupti, primary, Holdich, Tom, primary, Pandite, Lini, primary, Amado, Rafael, primary, and Mackall, Crystal L., primary

Published
2023
Full Text
View/download PDF

45. Data from Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors

Author

Chi, Ping, primary, Qin, Li-Xuan, primary, Camacho, Niedzica, primary, Kelly, Ciara M., primary, D'Angelo, Sandra P., primary, Dickson, Mark A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Rosenbaum, Evan, primary, Thornton, Katherine A., primary, Crago, Aimee M., primary, Francis, Jasmine H., primary, Martindale, Moriah, primary, Phelan, Haley T., primary, Biniakewitz, Matthew D., primary, Lee, Cindy J., primary, Singer, Samuel, primary, Hwang, Sinchun, primary, Berger, Michael F., primary, Chen, Yu, primary, Antonescu, Cristina R., primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Data from A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma

Author

Gounder, Mrinal M., primary, Rosenbaum, Evan, primary, Wu, Nian, primary, Dickson, Mark A., primary, Sheikh, Tahir N., primary, D'Angelo, Sandra P., primary, Chi, Ping, primary, Keohan, Mary Lou, primary, Erinjeri, Joseph P., primary, Antonescu, Cristina R., primary, Agaram, Narasimhan, primary, Hameed, Meera R., primary, Martindale, Moriah, primary, Lefkowitz, Robert A., primary, Crago, Aimee M., primary, Singer, Sam, primary, Tap, William D., primary, Takebe, Naoko, primary, Qin, Li-Xuan, primary, and Schwartz, Gary K., primary

Published
2023
Full Text
View/download PDF

47. Data from A Phase Ib/II Randomized Study of RO4929097, a Gamma-Secretase or Notch Inhibitor with or without Vismodegib, a Hedgehog Inhibitor, in Advanced Sarcoma

Author

Gounder, Mrinal M., primary, Rosenbaum, Evan, primary, Wu, Nian, primary, Dickson, Mark A., primary, Sheikh, Tahir N., primary, D'Angelo, Sandra P., primary, Chi, Ping, primary, Keohan, Mary Lou, primary, Erinjeri, Joseph P., primary, Antonescu, Cristina R., primary, Agaram, Narasimhan, primary, Hameed, Meera R., primary, Martindale, Moriah, primary, Lefkowitz, Robert A., primary, Crago, Aimee M., primary, Singer, Sam, primary, Tap, William D., primary, Takebe, Naoko, primary, Qin, Li-Xuan, primary, and Schwartz, Gary K., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure from Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors

Author

Chi, Ping, primary, Qin, Li-Xuan, primary, Camacho, Niedzica, primary, Kelly, Ciara M., primary, D'Angelo, Sandra P., primary, Dickson, Mark A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Rosenbaum, Evan, primary, Thornton, Katherine A., primary, Crago, Aimee M., primary, Francis, Jasmine H., primary, Martindale, Moriah, primary, Phelan, Haley T., primary, Biniakewitz, Matthew D., primary, Lee, Cindy J., primary, Singer, Samuel, primary, Hwang, Sinchun, primary, Berger, Michael F., primary, Chen, Yu, primary, Antonescu, Cristina R., primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figures 1 - 3, Tables 1 - 3 from Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers

Author

Dogan, Snjezana, primary, Shen, Ronglai, primary, Ang, Daphne C., primary, Johnson, Melissa L., primary, D'Angelo, Sandra P., primary, Paik, Paul K., primary, Brzostowski, Edyta B., primary, Riely, Gregory J., primary, Kris, Mark G., primary, Zakowski, Maureen F., primary, and Ladanyi, Marc, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Data from Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors

Author

Chi, Ping, primary, Qin, Li-Xuan, primary, Camacho, Niedzica, primary, Kelly, Ciara M., primary, D'Angelo, Sandra P., primary, Dickson, Mark A., primary, Gounder, Mrinal M., primary, Keohan, Mary L., primary, Movva, Sujana, primary, Nacev, Benjamin A., primary, Rosenbaum, Evan, primary, Thornton, Katherine A., primary, Crago, Aimee M., primary, Francis, Jasmine H., primary, Martindale, Moriah, primary, Phelan, Haley T., primary, Biniakewitz, Matthew D., primary, Lee, Cindy J., primary, Singer, Samuel, primary, Hwang, Sinchun, primary, Berger, Michael F., primary, Chen, Yu, primary, Antonescu, Cristina R., primary, and Tap, William D., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results